58580-07-7 Usage
Description
2-amino-5-bromo-3-nitrobenzoic acid is an organic compound characterized by its unique molecular structure, which features a benzoic acid backbone with a bromine atom at the 5th position, a nitro group at the 3rd position, and an amino group at the 2nd position. 2-amino-5-bromo-3-nitrobenzoic acid is known for its potential applications in various chemical and pharmaceutical processes due to its reactive functional groups.
Uses
Used in Pharmaceutical Industry:
2-amino-5-bromo-3-nitrobenzoic acid is used as a reactant for the preparation of substituted quinoxaline derivatives. These derivatives are known as PFKFB3 inhibitors, which play a crucial role in regulating cellular processes and have potential applications in the development of therapeutic agents for various diseases.
Check Digit Verification of cas no
The CAS Registry Mumber 58580-07-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,8,5,8 and 0 respectively; the second part has 2 digits, 0 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 58580-07:
(7*5)+(6*8)+(5*5)+(4*8)+(3*0)+(2*0)+(1*7)=147
147 % 10 = 7
So 58580-07-7 is a valid CAS Registry Number.
InChI:InChI=1/C7H5BrN2O4/c8-3-1-4(7(11)12)6(9)5(2-3)10(13)14/h1-2H,9H2,(H,11,12)
58580-07-7Relevant articles and documents
1, 4, 6-TRISUBSTITUTED-2-ALKYL-1H-BENZO[D]IMIDAZOLE DERIVATIVES AS DIHYDROOROTATE OXYGENASE INHIBITORS
-
, (2018/09/19)
The present invention provides 1, 4, 6-trisubstituted-2-alkyl-1H-benzo[d]imidazole derivatives as dihydroorotate oxygenase inhibitor compounds of formula (I), which may be therapeutically useful as DHODH inhibitors, in which R1 to R3
Process development for ABT-472, a benzimidazole PARP inhibitor
Barkalow, Jufang H.,Breting, Jeffrey,Gaede, Bruce J.,Haight, Anthony R.,Henry, Rodger,Kotecki, Brian,Mei, Jianzhang,Pearl, Kurt B.,Tedrow, Jason S.,Viswanath, Shekhar K.
, p. 693 - 698 (2012/12/29)
A nine-step convergent process was developed for the synthesis of ABT-472, a benzimidazole PARP inhibitor. The identity and origin of several impurities were determined, and the process was modified to reduce or eliminate these impurities. A number of safety and control issues were investigated. The original synthesis was shortened to 9 steps and streamlined while maintaining a convergent strategy. A stable salt was selected, and control of the API solid form was established. The process was successfully scaled up to provide 8.5 kg of final product of >99% purity in 33% yield over 9 steps.
